Recapitulating dengue virus infection with human pluripotent stem cell-derived liver organoids for antiviral screening.

阅读:4
作者:Li Meng-Qi, Xu Yan-Peng, Li Kai, Zhou Chao, Fan Xiao-Xuan, Wang Hui, Shi Pan-Deng, Li Rui-Ting, Wang Zu-Xin, Cao Tian-Shu, Chen Qi, Cui Yu-Jun, Deng Yong-Qiang, Wu Xiao-Yan, Zhao Hui, Qin Cheng-Feng
Dengue virus (DENV) poses a major global health threat, affecting an estimated 100 to 400 million people annually. The infection and pathogenesis remain incompletely understood, and no antiviral drug is currently approved for DENV treatment. Here, we develop a human pluripotent stem cell (hPSC)-derived liver organoid (hPLO) model to characterize DENV infection and screen for antivirals. The hPLOs, containing various liver cell types, are highly susceptible to DENV-2 infection, resulting in severe cell death and morphological changes that mimic the pathology observed in severe dengue cases. Single-cell RNA sequencing (scRNA-seq) of DENV-2 infected hPLOs reveals that proliferating hepatocyte-like cells are the primary target cells of DENV-2, with significant mitochondrial damage and alterations in cell-type composition. Further drug screening in hPLOs identifies oxyresveratrol (Oresveratrol, ORES) and omaveloxolone (RTA 408) as potent anti-DENV candidates. These compounds enhance resistance to DENV-2 infection by activating the NRF2 pathway, reducing oxidative stress, and preserving mitochondrial function. The efficacy of ORES and RTA 408 is further validated in the established AG6 mouse model. Our study not only establishes hPLOs as a valuable platform for studying DENV infection and pathogenesis, but also highlights the vital role of NRF2-mediated mitochondrial function for antiviral development.

特别声明

1、本文转载旨在传播信息,不代表本网站观点,亦不对其内容的真实性承担责任。

2、其他媒体、网站或个人若从本网站转载使用,必须保留本网站注明的“来源”,并自行承担包括版权在内的相关法律责任。

3、如作者不希望本文被转载,或需洽谈转载稿费等事宜,请及时与本网站联系。

4、此外,如需投稿,也可通过邮箱info@biocloudy.com与我们取得联系。